Login to Your Account

Is Natural Erythropoietin Bad, Too?

EPO Market Shaken By CMS' Plans To Cut Reimbursements

By Randall Osborne

Monday, July 30, 2007
Investor jitters eased somewhat as the Centers for Medicare & Medicaid Services' plans for reimbursement of erythropoietin (EPO) stimulating agents (ESAs) became clearer, and backers of Amgen Inc. found cause for encouragement on two fronts. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription